Neomics Pharmaceuticals

We are a preclinical stage bio-tech company.

Neomics has made a breakthrough in designing the third-generation chimeric proteins with high-expression levels equivalent to the widely used second-generation chimeric proteins. T cells expressing third-generation chimeric proteins manifest enhanced immune function.